ACOG - Alpha Cognition Inc

NYSE * Healthcare * Biotechnology

$5.80

$-0.10 (-1.78%)

About Alpha Cognition Inc

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.

Price Chart

+%
Loading chart...

ACOG Key Statistics

Market Cap

$132.39M

0

P/B Ratio

2.40

EPS

$-1.39

Revenue Growth

+0.2%

Profit Margin

-2.3%

Employees

71

How ACOG Compares to Peers

ACOG has the fastest revenue growth among competitors
ACOG is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

#6

of 6

Growth Rank

#1

of 6

Size Rank

#6

of 6

CompanyP/EGrowthCompare
ACOGN/A0%-
AMGN24.00%vs AMGN
GILD17.60%vs GILD
VRTX26.20%vs VRTX
REGN15.10%vs REGN
BIIB21.10%vs BIIB

Alpha Cognition Inc Company Information

Headquarters
1452 Hughes Street, Grapevine, TX, United States, 76051, undefined
Website
www.alphacognition.com
Sector
Healthcare
Industry
Biotechnology
Data Updated:
Ready to invest in ACOG?

Commission-free trading available. Affiliate links.

ACOG Lician Score

5% confidence
5.0/10
Neutral

ACOG has a Lician Score of 5/10 (Average). The stock shows average characteristics across all dimensions.

value

5.0

growth

4.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates ACOGacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

ACOG Financial Snowflake

5-axis analysis across key investment dimensions

4.8/10

Neutral

35810Value5.0Growth4.0Quality5.0Momentum5.0Safety5.04.8/10
5.0

Value

4.0

Growth

5.0

Quality

5.0

Momentum

5.0

Safety

Upcoming Events for ACOG